SCHEMBL4988913

SCHEMBL4988913

CCC(C)OC(=O)C(NC(=O)c1ccc(N)cn1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.39
GRM5 P41594 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
AKR1B1 P15121 1/20 0.36
MAPT P10636 1/20 0.35
GABRA1 P14867 3/20 0.35
GABRG2 P18507 3/20 0.35
GABRB3 P28472 3/20 0.35
GABRA5 P31644 3/20 0.35
GABRA3 P34903 3/20 0.35
GABRA2 P47869 3/20 0.35
GABRA6 Q16445 1/20 0.35
HDAC3 O15379 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
CTSA P10619 1/20 0.34
KMT2A Q03164 1/20 0.34
FPR2 P25090 2/20 0.34
HIF1A Q16665 1/20 0.34
HDAC4 P56524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4985552 0.87 TRPA1 (0.41) CHRM2GRM5SIGMAR1MAPT
SCHEMBL4988590 0.87 XIAP (0.40) CHRM2GRM5SIGMAR1AKR1B1MAPT
SCHEMBL4991288 0.86 CHRM2 (0.39) CHRM2GRM5SIGMAR1HDAC3HDAC1
SCHEMBL4985300 0.86 HCAR3 (0.45) CHRM2GRM5SIGMAR1MAPT
SCHEMBL4990235 0.81 ALDH1A1 (0.42) MAPT
SCHEMBL4990580 0.81 ACACB (0.49) MAPTKMT2A
SCHEMBL4985590 0.79 TRPA1 (0.40) HDAC3HDAC1HDAC8FPR2HDAC4
SCHEMBL4988226 0.79 LMNA (0.41) MAPTGABRA1GABRG2GABRB3GABRA5
SCHEMBL4988893 0.79 LMNA (0.40) CHRM2GRM5SIGMAR1GABRA1GABRG2
SCHEMBL4990205 0.79 SMN1; SMN2 (0.47) MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080125409-A1 1,5-Diheterocycle-1H-Triazole Derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-05-29 US disclosed
EP-1803719-A1 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-07-04 EP disclosed
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125409-A1 1,5-Diheterocycle-1H-Triazole Derivative PTGS1, PTGER1, TBXA2R CHRM2 2721/4885GRM5 610/4885SIGMAR1 1015/4885
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 CHRM2 4866/4885GRM5 1490/4885SIGMAR1 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.